TetraLogic Financial Statements From 2010 to 2025
| TLOG Stock | USD 0.0001 0.00 0.00% |
Check TetraLogic Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TetraLogic Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . TetraLogic financial statements analysis is a perfect complement when working with TetraLogic Pharmaceuticals Valuation or Volatility modules.
TetraLogic |
TetraLogic Pharmaceuticals Corp Company Return On Asset Analysis
TetraLogic Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current TetraLogic Pharmaceuticals Return On Asset | -0.2 |
Most of TetraLogic Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TetraLogic Pharmaceuticals Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, TetraLogic Pharmaceuticals Corp has a Return On Asset of -0.1959. This is 97.76% lower than that of the Biotechnology sector and 99.17% lower than that of the Health Care industry. The return on asset for all United States stocks is 39.93% higher than that of the company.
TetraLogic Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining TetraLogic Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare TetraLogic Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across TetraLogic Pharmaceuticals competition to find correlations between indicators driving TetraLogic Pharmaceuticals's intrinsic value. More Info.TetraLogic Pharmaceuticals Corp is currently regarded as top stock in return on asset category among its peers. It is rated second in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the TetraLogic Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About TetraLogic Pharmaceuticals Financial Statements
TetraLogic Pharmaceuticals stakeholders use historical fundamental indicators, such as TetraLogic Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although TetraLogic Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in TetraLogic Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on TetraLogic Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in TetraLogic Pharmaceuticals Corp. Please read more on our technical analysis and fundamental analysis pages.
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. Tetralogic Pharmaceu operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 29 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in TetraLogic Pink Sheet
TetraLogic Pharmaceuticals financial ratios help investors to determine whether TetraLogic Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in TetraLogic with respect to the benefits of owning TetraLogic Pharmaceuticals security.